StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) shareholders

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
53.5%
110M of 207M shares
Institutional holders
226
39 new, 24 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
1 buys · 63 sales
Net bought $333.39M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Roivant Sciences Ltd.113,327,00755.90%13D (active) amendmentDec 12, 2025
FMR LLC
Joint filing with Abigail P. Johnson (10.10%)
17,078,09310.10%13G (passive) amendmentFeb 28, 2025
Abigail P. Johnson
Joint filing with FMR LLC (8.40%)
14,729,5558.40%13G (passive) amendmentSep 30, 2025
Deep Track Biotechnology Master Fund, Ltd.
Joint filing with Deep Track Capital, LP (5.59%), David Kroin (5.59%)
9,500,0005.59%13G (passive)Mar 19, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of IMVTValueChange% of portfolio
FMR LLC16,186,4697.84%$623.66M−761,4190.03%
Deep Track Capital, LP9,341,1514.52%$359.91M−2,185,8205.24%
BlackRock, Inc.7,180,8973.48%$276.68M+606,4000.00%
Farallon Capital Management LLC5,805,0002.81%$223.67M+4,259,0001.03%
Baker Bros. Advisors LP5,435,2202.63%$209.42M−22,6611.05%
State Street Corp4,617,0052.24%$177.89M+79,0760.01%
Morgan Stanley4,534,8332.20%$174.73M+657,9560.01%
TCG Crossover Management, LLC4,457,9882.16%$171.77M–4.13%
Vanguard Portfolio Management LLC3,910,5091.89%$150.67M+205,6040.01%
Vanguard Capital Management LLC3,638,6811.76%$140.20M+18,6310.00%
Jennison Associates LLC3,310,2381.60%$127.54M+113,5330.08%
Rtw Investments, LP3,177,8491.54%$122.44M–1.05%
Two Seas Capital LP3,148,5051.52%$121.31M−53,4572.40%
ADAR1 Capital Management, LLC2,330,7161.13%$89.80M−348,2944.11%
Geode Capital Management, LLC2,234,6021.08%$86.12M+142,5000.00%
T. Rowe Price Investment Management, Inc.2,222,1011.08%$85.62M−1,390,7590.06%
Woodline Partners LP1,975,8690.96%$76.13M–0.24%
Price T Rowe Associates Inc /Md/1,829,2100.89%$70.48M+1,489,6030.01%
Goldman Sachs Group Inc1,751,1830.85%$67.47M−33,9240.01%
Armistice Capital, LLC1,736,0000.84%$66.89M−1,828,9160.82%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026226110M53.5%39 / 7479 / 2413M14M
Q1 2026215111M53.9%46 / 9340 / 2522M12M
Q4 2025197109M52.9%40 / 7554 / 2623M9M
Q3 202518695M46.1%35 / 6451 / 169M10M
Q2 202516896M46.6%24 / 7447 / 4811M10M
Q1 202519395M45.9%36 / 9143 / 2722M9M
Q4 202418682M39.8%38 / 6861 / 2914M11M
Q3 202418280M38.6%21 / 7166 / 3517M8M
Q2 202419776M36.6%25 / 8166 / 3515M15M
Q1 202420975M36.3%28 / 8279 / 4615M11M
Q4 202322872M34.6%72 / 6872 / 2417M13M
Q3 202318168M33.0%61 / 6444 / 2423M11M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

204 funds held IMVT in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of IMVTValue% of fundAs of
Fidelity Growth Company Fund5,098,6312.47%$169.78M0.17%May 31, 2026
Vanguard Total Stock Market Index Fund2,600,0861.26%$100.18M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,576,5561.25%$99.27M0.92%Jun 30, 2026
iShares Russell 2000 ETF2,190,1571.06%$84.39M0.10%Jun 30, 2026
Vanguard Small-Cap Index Fund1,881,7980.91%$72.51M0.04%Jun 30, 2026
Fidelity Growth Company K6 Fund1,402,5780.68%$46.71M0.17%May 31, 2026
Fidelity Series Growth Company Fund1,113,7590.54%$37.09M0.15%May 31, 2026
Vanguard Small-Cap Growth Index Fund1,086,2900.53%$41.85M0.09%Jun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.991,4660.48%$38.20M0.41%Jun 30, 2026
PGIM Jennison Small Company Fund981,5410.48%$37.82M1.09%Jun 30, 2026
Fidelity Small Cap Index Fund932,9800.45%$36.03M0.11%Jul 31, 2026
Vanguard Extended Market Index Fund887,9050.43%$34.21M0.04%Jun 30, 2026
iShares Russell 2000 Growth ETF787,6450.38%$30.35M0.20%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund642,0000.31%$24.74M0.25%Jun 30, 2026
iShares Biotechnology ETF573,7470.28%$22.11M0.24%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Eric VenkerChief Executive Officer, Director257,0750.12%Oct 5, 2026
Peter SalzmannChief Executive Officer, Director1,178,1910.57%Apr 17, 2025
Tiago GiraoChief Financial Officer234,1920.11%Oct 30, 2026
Jay S. StoutChief Technology Officer198,9370.10%Oct 23, 2026
Tuyl Christopher VanChief Legal Officer175,2180.08%Oct 9, 2026
Melanie GloriaChief Operating Officer217,0600.11%Oct 9, 2026
Michael GeffnerChief Medical Officer217,9580.11%Oct 24, 2025
Eva Renee BarnettChief Financial Officer396,7740.19%Apr 17, 2025
William L. MaciasChief Medical Officer357,3530.17%Feb 21, 2025
Mark S. LevineChief Legal Officer319,2280.15%Nov 22, 2024
Atul PandeDirector136,7310.07%Nov 12, 2026
Andrew J. FromkinDirector131,4000.06%May 29, 2026
Robert Graham SusmanDirector36,3940.02%May 1, 2026
Douglas J. HughesDirector134,6530.07%Apr 9, 2026
Jake BauerDirector38,8960.02%Apr 9, 2026
Frank TortiDirector1,009,2280.49%Apr 9, 2026
Sciences Ltd. RoivantDirector, 10% owner113,317,00754.86%Dec 12, 2025
George V. MigauskyDirector157,2510.08%Apr 3, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Atul Pande
Director
Nov 11, 2026Sale(10b5-1 plan)−3,000$36.00$108.00K116,731
Atul Pande
Director
Nov 11, 2026Option exercise+3,000$8.43$25.29K119,731
Tiago Girao
Chief Financial Officer
Oct 28, 2026Sale−6,606$28.50$188.27K234,192
Jay S. Stout
Chief Technology Officer
Oct 21, 2026Sale−2,595$28.94$75.10K198,937
Tuyl Christopher Van
Chief Legal Officer
Oct 7, 2026Sale−1,327$32.06$42.54K175,218
Melanie Gloria
Chief Operating Officer
Oct 7, 2026Sale−2,241$32.06$71.85K217,060
Jay S. Stout
Chief Technology Officer
Oct 7, 2026Sale−1,596$32.06$51.17K201,532
Jay S. Stout
Chief Technology Officer
Oct 7, 2026Sale−2,213$32.06$70.95K203,128
Eric Venker
Chief Executive Officer, Director
Oct 2, 2026Sale−3,506$34.11$119.59K257,075
Eric Venker
Chief Executive Officer, Director
Oct 1, 2026Returned to company−85,886$33.65$2.89M260,581
Eric Venker
Chief Executive Officer, Director
Oct 1, 2026Option exercise+92,187$14.46$1.33M346,467
Tuyl Christopher Van
Chief Legal Officer
Sep 23, 2026Sale−2,846$36.36$103.48K176,545
Atul Pande
Director
Aug 28, 2026Option exercise+1,500$8.43$12.65K118,231
Atul Pande
Director
Aug 28, 2026Sale(10b5-1 plan)−1,500$43.27$64.91K116,731
Melanie Gloria
Chief Operating Officer
Aug 20, 2026Sale−3,056$44.16$134.95K219,301
Atul Pande
Director
Jul 24, 2026Sale(10b5-1 plan)−1,500$39.80$59.70K116,731
Atul Pande
Director
Jul 24, 2026Option exercise+1,500$8.43$12.65K118,231
Tiago Girao
Chief Financial Officer
Jul 23, 2026Sale−6,798$38.69$263.01K240,798
Jay S. Stout
Chief Technology Officer
Jul 23, 2026Sale−2,857$38.69$110.54K205,341
Jay S. Stout
Chief Technology Officer
Jul 8, 2026Sale−1,906$39.53$75.34K209,779
Jay S. Stout
Chief Technology Officer
Jul 8, 2026Sale−105$39.99$4.20K209,674
Jay S. Stout
Chief Technology Officer
Jul 8, 2026Sale−77$39.99$3.08K208,198
Jay S. Stout
Chief Technology Officer
Jul 8, 2026Sale−1,399$39.53$55.30K208,275
Tuyl Christopher Van
Chief Legal Officer
Jul 8, 2026Sale−1,143$39.53$45.18K179,454
Tuyl Christopher Van
Chief Legal Officer
Jul 8, 2026Sale−63$39.99$2.52K179,391
Melanie Gloria
Chief Operating Officer
Jul 8, 2026Sale−1,930$39.53$76.29K222,463
Melanie Gloria
Chief Operating Officer
Jul 8, 2026Sale−106$39.99$4.24K222,357
Eric Venker
Chief Executive Officer, Director
Jul 2, 2026Sale−3,092$38.48$118.98K254,280
Eric Venker
Chief Executive Officer, Director
Jul 1, 2026Option exercise+92,188$14.46$1.33M344,001
Eric Venker
Chief Executive Officer, Director
Jul 1, 2026Returned to company−86,629$38.14$3.30M257,372
Melanie Gloria
Chief Operating Officer
Jun 26, 2026Sale−2,966$38.95$115.53K224,393
Melanie Gloria
Chief Operating Officer
Jun 26, 2026Sale−14,748$38.18$563.08K227,359
Jay S. Stout
Chief Technology Officer
Jun 26, 2026Sale−33,277$38.18$1.27M218,408
Jay S. Stout
Chief Technology Officer
Jun 26, 2026Sale−6,723$38.94$261.79K211,685
Atul Pande
Director
Jun 26, 2026Sale(10b5-1 plan)−1,500$38.01$57.02K116,731
Atul Pande
Director
Jun 26, 2026Option exercise+1,500$8.43$12.65K118,231
Tuyl Christopher Van
Chief Legal Officer
Jun 26, 2026Option exercise+17,824$15.20$270.92K198,421
Tuyl Christopher Van
Chief Legal Officer
Jun 26, 2026Sale−14,982$38.19$572.16K183,439
Tuyl Christopher Van
Chief Legal Officer
Jun 26, 2026Sale−2,842$38.96$110.72K180,597
Tiago Girao
Chief Financial Officer
Jun 26, 2026Option exercise+10,000$15.90$159.00K257,596
Tiago Girao
Chief Financial Officer
Jun 26, 2026Sale−10,000$38.46$384.60K247,596
Tuyl Christopher Van
Chief Legal Officer
Jun 18, 2026Sale−2,634$35.39$93.22K180,597
Atul Pande
Director
Jun 15, 2026Option exercise+1,500$8.43$12.65K118,231
Atul Pande
Director
Jun 15, 2026Sale(10b5-1 plan)−1,500$34.02$51.03K116,731
Andrew J. Fromkin
Director
May 28, 2026Option exercise+31,668$4.99$158.02K131,400
Andrew J. Fromkin
Director
May 28, 2026Option exercise+71,492$7.94$567.65K202,892
Andrew J. Fromkin
Director
May 28, 2026Option exercise+16,260$14.70$239.02K296,333
Andrew J. Fromkin
Director
May 28, 2026Sale−11,483$32.64$374.81K284,850
Andrew J. Fromkin
Director
May 28, 2026Sale−210,468$33.56$7.06M74,382
Andrew J. Fromkin
Director
May 28, 2026Option exercise+77,181$8.43$650.64K280,073
Melanie Gloria
Chief Operating Officer
May 20, 2026Sale−1,168$32.15$37.55K243,805
Melanie Gloria
Chief Operating Officer
May 20, 2026Sale−1,698$32.95$55.95K242,107
Melanie Gloria
Chief Operating Officer
May 20, 2026Sale−249$30.41$7.57K244,973
Atul Pande
Director
May 20, 2026Sale(10b5-1 plan)−6,000$32.00$192.00K116,731
Atul Pande
Director
May 20, 2026Option exercise+6,000$8.43$50.58K122,731
Robert Graham Susman
Director
May 1, 2026Sale(10b5-1 plan)−2,502$27.17$67.98K36,394
Jay S. Stout
Chief Technology Officer
Apr 23, 2026Sale−2,754$29.62$81.57K251,685
Tiago Girao
Chief Financial Officer
Apr 23, 2026Sale−25,760$29.62$763.01K247,596
Tuyl Christopher Van
Chief Legal Officer
Apr 8, 2026Sale−5,165$24.83$128.25K183,231
Jay S. Stout
Chief Technology Officer
Apr 8, 2026Sale−1,518$24.83$37.69K254,439

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
21.07%
19M shares short
Days to cover
15.3
At 1M shares a day
Change since last report
+1.5%
From 18M shares
Short volume, 20 days
51.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immunovant's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,669 shares on Sep 4, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jay S. Stout
Officer
Jun 26, 202640,000$1.53MJun 26, 2026Restricted Stock Vesting Under a Registered Plan
Chris Adair Van Tuyl
Officer, Director
Jun 26, 202617,824$682.80KJun 26, 2026Exercise of Options Under a Registered Plan
Melanie Gloria
Officer
Jun 26, 202617,714$678.55KJun 26, 2026Restricted Stock Vesting Under a Registered Plan
Tiago Girao
Officer
Jun 26, 202610,000$384.64KJun 26, 2026Exercise of Options Under a Registered Plan
Atul Pande
Director
Jun 15, 20266,000$201.72KJun 15, 2026Exercise of Stock Options
Andrew J. Fromkin
Director
May 28, 2026221,951$7.44MMay 28, 2026Exercise of options under a registered plan
Atul Pande
Director
May 20, 20266,000$157.74KMay 20, 2026Exercise of Stock Options
Robert Graham Susman
Director
May 1, 20262,502$67.92KMay 1, 2026Restricted Stock Units
Michael Geffner
Officer
Feb 10, 20265,800$155.24KFeb 10, 2026Restricted Stock
Andrew J. Fromkin
Director
Dec 1, 202522,249$537.31KDec 1, 2025Restricted Stock Units
Douglas J. Hughes
Director
Dec 1, 202515,000$362.25KDec 1, 2025Restricted Stock Units
Michael Geffner
Officer
Nov 26, 202550,000$1.19MNov 26, 2025Stock Option Exercise
Michael Geffner
Officer
Nov 25, 2025103,897$2.43MNov 25, 2025Stock Option Exercise
William L. Macias
Officer
Jun 25, 202530,000$474.86KJun 25, 2025Restricted Stock
William L. Macias
Officer
Jun 13, 202550,000$778.49KJun 13, 2025Restricted Stock

See a number that looks wrong?